Skip to main content

videos

Matthew Davids, MD
Conference Coverage
01/05/2026
Matthew S. Davids, MD, MMSc
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Matthew Davids, MD
Conference Coverage
01/05/2026
Matthew S. Davids, MD, MMSc
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Joseph Mikhael, MD
Conference Coverage
01/05/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the...
01/05/2026
Oncology
Joseph Mikhael, MD
Conference Coverage
01/05/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the...
01/05/2026
Oncology
Adriana Rossi, MD
Conference Coverage
01/02/2026
Adriana Rossi, MD
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the...
01/02/2026
Oncology
Adriana Rossi, MD
Conference Coverage
01/02/2026
Adriana Rossi, MD
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the...
01/02/2026
Oncology
Joshua Richter, MD
Conference Coverage
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology
Joshua Richter, MD
Conference Coverage
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology
Mark Bustoros, MD
Conference Coverage
12/01/2025
Mark Bustoros, MD
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...
12/01/2025
Oncology
Mark Bustoros, MD
Conference Coverage
12/01/2025
Mark Bustoros, MD
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...
12/01/2025
Oncology